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Dietary interventions have emerged as effective environmental inducers of brain plasticity. Among these dietary interventions,
we here highlight the impact of caloric restriction (CR: a consistent reduction of total daily food intake), intermittent fasting (IF,
every-other-day feeding), and diet supplementation with polyphenols and polyunsaturated fatty acids (PUFAs) onmarkers of brain
plasticity in animal studies. Moreover, we also discuss epidemiological and intervention studies reporting the effects of CR, IF and
dietary polyphenols and PUFAs on learning, memory, and mood. In particular, we evaluate the gap in mechanistic understanding
between recent findings from animal studies and those human studies reporting that these dietary factors can benefit cognition,
mood, and anxiety, aging, and Alzheimer’s disease—with focus on the enhancement of structural and functional plasticity markers
in the hippocampus, such as increased expression of neurotrophic factors, synaptic function and adult neurogenesis. Lastly,
we discuss some of the obstacles to harnessing the promising effects of diet on brain plasticity in animal studies into effective
recommendations and interventions to promote healthy brain function in humans. Together, these data reinforce the important
translational concept that diet, a modifiable lifestyle factor, holds the ability to modulate brain health and function.
1. Introduction
One of the most remarkable capabilities of the brain is its
ability to change in response to different stimuli. Among
the highly sensitive, environment-responsive structures of
the brain is the hippocampus, a region extensively known
to regulate learning, memory, and mood [1–7]. Indeed,
the expression of long-lasting activity-dependent synaptic
modifications in response to stimuli of high frequency is
an established phenomenon of the hippocampal neural cir-
cuitry [8]. This process of long-term potentiation (LTP) is
considered as a prominent mechanism underlying learning
and memory formation in the mammalian brain [9, 10].
Another hallmark of the hippocampus, in particular in its
subregion which is called the dentate gyrus (DG), is the
well-established capability of continual generation of new
functional neurons throughout postnatal life.This process of
adult hippocampal neurogenesis (AHN) is characterized by
the presence of neural stem cells (NSC) with the ability to
self-renew and differentiate into mature neurons [11] as well
as by the microenvironment of the neurogenic niche, which
engages the signalling pathways governing both proliferative
activity and neuronal differentiation [12]. Functionally, AHN
has been demonstrated to be essential for cognitive and
emotional regulation, with its ablation or partial disruption,
leading to severe impairment of learning abilities as well as
increased depressive- and anxiety-related behaviors [13–17].
AHN is a highly regulated mechanism, meaning that the
generation,migration, and integration of newly born neurons
into preexisting circuits depend on complex signaling within
the neurogenic niche [12]. NSC in the DG exist in close
contact with local blood vessels [18]; this proximity is believed
to aid the delivery of biochemical stimuli from the systemic
milieu to the DG [19]. In turn, this can directly affect AHN
for better, through the delivery of food-derived components
to be used as precursors of neurotransmitters, or worse,
by the exposure of the neurogenic niche to age-related
inflammatory markers that inhibit neurogenesis [19].
A number of environmental factors have been shown
to alter markers of brain plasticity, inducing changes not
only in AHN [20, 21], but also of synaptogenesis [22],
dendritic arborization [23], and spinogenesis [24], which
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in turn provide the biological substrate for adaptation to
different environmental conditions [25, 26]. For instance,
human stress reflects the increasing environmental chal-
lenges present in our society and actively modulates hip-
pocampal structure and function, among other brain regions
[27]. Indeed, animal studies have revealed that chronic stress
reduces the dendritic tree of hippocampal neurons [28].
In contrast, voluntary exercise has been extensively shown
to promote the local synthesis of growth factors, including
brain-derived neurotrophic factor (BDNF) [21, 29] and to
enhance AHN/angiogenesis [30].
Diet—encompassing total intake, frequency, and
content—is also an important environmental factor that
impacts brain plasticity, including AHN [31, 32]. Although
there is much to be unravelled with regard to the specific
molecular mechanisms through which dietary factors impact
brain plasticity, a great body of literature supports the notion
that diet modulates brain structure and function, exerting
its influence throughout the lifespan of an organism. In this
review, we primarily focus on studies from 2010 onwards
that have investigated the effects of diet on markers of
postnatal/adult brain plasticity, including AHN, trophic
factors, and synaptic function. In particular, we review the
effects of calorie restriction (CR), intermittent fasting (IF),
polyphenols, and poly-unsaturated fatty acids (PUFAs) on
the cellular and molecular mechanisms that underlie brain
plasticity in context of cognition, mood/anxiety, aging, and
Alzheimer’s disease (AD) in both animal and human studies.
Although full coverage of all relevant studies is not possi-
ble given the broad scope of this review, the presentwork aims
to evaluate the translational gap between the results from
animal studies exploring the impact of diet upon markers
of brain plasticity versus data from epidemiological and
clinical intervention studies that suggest that diet influences
both cognitive and emotional regulations across different
disease contexts. Finally, we discuss some of the obstacles of
harnessing the promising effects of diet on brain plasticity
from animal studies into effective recommendations and
interventions to promote healthy brain function in humans.
2. Calorie Restriction: Effects of
Reducing What You Eat
2.1. Background and Physiological/Molecular Mechanisms of
CR. The effects of CR—limiting calorie intake compared
to baseline unrestricted or ab libitum (AL) consumption,
with maintained levels of vitamin, mineral, or other essen-
tial biomolecules [33]—have attracted significant scientific
attention since the pioneering work of McCay and colleagues
showing that this intervention markedly extends the lifespan
of rats [34]. In addition, CR was subsequently seen to entail
significant benefits for “healthspan,” a term which describes
the years of our life lived free of pathology and disease
[35]. In this regard, CR has been shown to improve insulin
sensitivity and autonomic function, as well as delay the onset
of age-related process in many organisms ranging from yeast,
worms, and flies [33] to higher mammals [36, 37]. Moreover,
in human subjects, CR results in amultitude of health benefits
[38], including reductions in abdominal fat mass, increased
insulin sensitivity, and reduced levels of proinflammatory
cytokines, reactive oxygen species, and atherosclerotic lipids
in the blood [39, 40].
Theoretically, CR can be regarded as an example of
hormesis, whereby too much of something evokes a detri-
mental response, whereas a smaller exposure but still above
the normal range induces amild stress that is in fact beneficial
[38]. The signaling pathways involved culminate in the pro-
duction of adaptive stress-response molecules that enhance
the ability of the brain to resist more severe stress in the
event of larger insults by promoting cell repair and survival,
including trophic factors, antioxidant enzymes, DNA-repair
enzymes,and proteins involved in mitochondrial biogenesis
[38, 41]. It is likely that the beneficial effects of CR are a
result of synergistic and/or additive effects of these multiple
mechanisms.
It must be emphasised from the outset that CR is highly
inappropriate for some groups of individuals, despite the
putative benefits for metabolic health and brain plasticity
discussed herein. In particular, CR is not a viable intervention
for young children or pregnant women, where consistent
adherence to a balanced diet is of paramount importance for
physical development.
2.2. Impact of CR on Brain Plasticity. CR appears to both
improve the resilience of synapses to metabolic and oxidative
damage and modulate the total number, structure, and
functional status of synapses [38]. In addition, maintenance
on a CR regimen resulted in the differential expression of a
multitude of genes, 25% of which were implicated in synaptic
plasticity [42].
Interestingly, CR is associated with greater electrical
and synaptic activity throughout neuronal circuits when
compared to satiated and resting states [43]. In addition,
CR stabilizes the levels of glutamate receptors and synaptic
proteins required for excitatory transmission and thought
to underlie hippocampal-dependent learning and memory
[43, 44]. The generation of neurotrophic factors is another
important adaptive and neuroprotective response to CR [45].
Table 1 outlines recent animal studies investigating the
molecular players underlying the effects of CR on brain
plasticity. For example, a role for the cAMP responsive-
element binding-1 (CREB-1) has recently been suggested.
Mice lacking the expression of this transcription factor in
the forebrain were unable to exhibit the expected beneficial
effects of CR on neuronal plasticity (enhanced LTP), memory
(improved object recognition), and social behavior (reduced
aggressiveness) when submitted to a 70% CR for a period of
5 weeks [46].
Long-term CR has also been shown to elicit working
memory improvement in mice [47, 48]. In addition, sig-
nificant increases in the expression of the NMDA receptor
subunits NR2A and NR2B, essential for LTP and synaptic
plasticity, were found in the hippocampus of 60% CR obese
rats in comparison with age-matched AL-fed obese animals
[49].
Neural Plasticity 3
Ta
bl
e
1:
Eff
ec
ts
of
di
et
on
br
ain
pl
as
tic
ity
an
d
co
gn
iti
on
in
an
im
al
stu
di
es
fro
m
20
10
on
wa
rd
s.
M
od
el
D
iet
ar
yf
ac
to
r
In
te
rv
en
tio
n
Ce
llu
lar
an
d
m
ol
ec
ul
ar
m
ec
ha
ni
sm
s
Eff
ec
ts
on
be
ha
vi
or
Co
nc
lu
sio
n/
pr
op
os
ed
m
ec
ha
ni
sm
Re
fe
re
nc
e
5-
we
ek
-o
ld
m
ale
W
ist
ar
ra
ts
EP
A-
E
1.0
m
g/
g/
da
yf
or
8
we
ek
sv
ia
ga
va
ge
↑LTPin
CA
1,
↑hippoc
am
pa
l
p8
5훼
N
/A
EP
A
ex
er
ts
ne
ur
op
ro
te
ct
iv
e
eff
ec
ts
vi
as
yn
ap
tic
pl
as
tic
ity
en
ha
nc
em
en
t
[17
6]
4-
m
on
th
-o
ld
ob
es
ea
nd
no
no
be
se
m
ale
W
ist
ar
ra
ts
60
%
CR
10
we
ek
s
↑hippoc
am
pa
lN
R2
A
an
d
N
R2
B
lev
els
in
CR
ob
es
er
at
s;
↓MDAl
ev
els
in
all
CR
gr
ou
ps
N
/A
CR
pr
ev
en
ts
ox
id
at
iv
es
tre
ss
,
pr
ot
ec
tin
gN
M
DA
R
su
bu
ni
ts
2A
an
d
2B
in
ob
es
er
at
sw
hi
ch
ca
n
re
su
lt
in
↑LTPan
d
sy
na
pt
ic
pl
as
tic
ity
[4
9]
3-
m
on
th
-o
ld
fe
m
ale
Ca
lif
or
ni
am
ice
80
%
CR
8w
ee
ks
in
SD
or
LD
ph
ot
op
er
io
d
N
o
CR
-in
du
ce
d
ch
an
ge
si
n
hi
pp
oc
am
pa
ls
yn
ap
sin
Io
r
G
FA
P
↓perform
an
ce
in
LD
m
ice
in
re
ve
rs
al
lea
rn
in
g(
Ba
rn
es
m
az
e)
Eff
ec
ts
of
CR
on
sp
at
ia
l
lea
rn
in
ga
re
ph
ot
op
er
io
d
de
pe
nd
en
t
[4
8]
6-
m
on
th
-o
ld
BC
KO
m
ice
70
%
CR
5w
ee
ks
↓LTPin
CR
co
nt
ro
ls
bu
tn
ot
in
BC
KO
↑memor
ya
nd
↓aggress
iv
en
es
si
n
CR
co
nt
ro
ls
bu
tn
ot
in
BC
KO
CR
eff
ec
ts
de
pe
nd
on
CR
EB
-1
by
its
re
gu
lat
io
n
of
sir
tu
in
tra
ns
cr
ip
tio
n
in
ne
ur
on
al
ce
lls
[4
6]
12
–1
4-
we
ek
-o
ld
m
ale
SH
RS
P
ra
ts
70
%
CR
28
da
ys
or
28
da
ys
of
CR
+
EX
tra
in
in
g
↑hippoc
am
pa
lB
D
N
F
in
CR
+
EX
ra
ts
↑cogniti
on
(M
W
M
)i
n
CR
+
EX
ra
ts
CR
+
EX
ac
ts
yn
er
gi
sti
ca
lly
to
up
re
gu
lat
eB
D
N
F
an
d
pr
ev
en
t
co
gn
iti
ve
de
cli
ne
in
SH
RS
P
ra
ts
[5
1]
∼3-mon
th
-o
ld
m
ale
Sp
ra
gu
e-
D
aw
ley
ra
ts
IF
or
AD
X
+
IF
or
IF
+
KA
or
AD
X
+
IF
+
KA
14
we
ek
s
↓CA2/C
A3
ce
ll
lo
ss
by
IF
an
d
AD
X
+
IF
aft
er
KA
in
su
lt;
↑BDNF
an
d
pC
RE
B
in
AD
X
+
IF
on
ly
At
te
nu
at
ed
KA
-in
du
ce
d
lea
rn
in
gd
efi
cit
in
aT
-m
az
e
ta
sk
by
AD
X
+
IF
IF
pr
ot
ec
ts
hi
pp
oc
am
pa
l
ne
ur
on
sa
ga
in
st
KA
in
su
lt;
IF
eff
ec
ts
ar
e↑under
lo
we
rl
ev
els
of
CO
RT
[10
7]
10
–1
2-
we
ek
-o
ld
m
ale
C5
7B
L/
6
m
ice
;C
G
RP
−/−
m
ice
RE
S
20
m
g/
L
or
all
y
ad
m
in
ist
er
ed
on
ce
da
ily
fo
r3
we
ek
s
↑hippoc
am
pa
lC
G
RP
,I
G
F-
I
an
d
IG
F-
Im
RN
A;
↑angioge
ne
sis
an
d
AH
N
;n
o
eff
ec
ts
in
CG
RP
−/−mic
e
↑spatial
lea
rn
in
g(
M
W
M
);
no
eff
ec
ts
on
CG
RP
−/−
m
ice
RE
Ss
tim
ul
at
es
se
ns
or
y
ne
ur
on
si
n
th
eG
It
ra
ct
,
↑IGF-Ip
ro
du
ct
io
n
an
d
pr
om
ot
in
ga
ng
io
ge
ne
sis
an
d
AH
N
,t
he
re
by
↑cogniti
on
[13
2]
38
-m
on
th
-o
ld
m
ale
gr
ey
m
ou
se
lem
ur
s
70
%
CR
or
RE
S
70
%
CR
or
RE
S
(2
00
m
g/
kg
/d
ay
)f
or
18
m
on
th
s
N
/A
di
re
ct
ly
;s
im
ila
rl
ev
els
of
se
ru
m
CO
RT
↑workin
gm
em
or
y(
CS
A)
;
↑spatial
pe
rfo
rm
an
ce
(C
PT
)o
nl
yi
n
RE
Sg
ro
up
CR
an
d
RE
Ss
ee
m
to
in
du
ce
sim
ila
rb
en
efi
ts
on
co
gn
iti
ve
fu
nc
tio
ns
in
an
ad
ul
tp
rim
at
e
by
pr
ob
ab
ly
ac
tiv
at
in
g
str
iat
op
re
fro
nt
al
cir
cu
its
an
d
hi
pp
oc
am
pu
s
[13
4]
10
-w
ee
k-
ol
d
m
ale
W
ist
ar
ra
ts
Bl
ue
be
rr
y
2%
fo
r7
we
ek
s
Ac
tiv
at
io
n
of
ER
K1
/2
;
↑CREB;
↑pro-an
d
m
BD
N
F
in
th
eh
ip
po
ca
m
pu
s;
↑BDNF
m
RN
A
in
th
eD
G
an
d
CA
1
↑spatial
lea
rn
in
gi
n
a
de
lay
ed
no
nm
at
ch
ta
sk
(8
-a
rm
m
az
e)
Fl
av
on
oi
d-
ric
h
bl
ue
be
rr
ies
↑spatial
lea
rn
in
gi
n
yo
un
g
he
alt
hy
ra
ts,
lik
ely
th
ro
ug
h
ac
tiv
at
io
n
of
ER
K-
CR
EB
-B
D
N
F
pa
th
wa
yi
n
th
eh
ip
po
ca
m
pu
s
[12
8]
4 Neural Plasticity
Ta
bl
e
1:
Co
nt
in
ue
d.
M
od
el
D
iet
ar
yf
ac
to
r
In
te
rv
en
tio
n
Ce
llu
lar
an
d
m
ol
ec
ul
ar
m
ec
ha
ni
sm
s
Eff
ec
ts
on
be
ha
vi
or
Co
nc
lu
sio
n/
pr
op
os
ed
m
ec
ha
ni
sm
Re
fe
re
nc
e
8-
we
ek
-o
ld
m
ale
W
ist
ar
ra
ts
Fl
av
on
oi
ds
8.7
m
g/
da
yo
r
17.
4m
g/
da
yf
or
3
we
ek
s
↑PSA-N
CA
M
in
th
eD
G
an
d
N
M
DA
-N
R2
B
in
th
e
hi
pp
oc
am
pu
s;
↑ERK/C
RE
B/
BD
N
F
sig
na
lin
g,
an
d
↑activati
on
of
th
e
Ak
t/m
TO
R/
Ar
cp
at
hw
ay
↑spatial
m
em
or
y
ac
qu
isi
tio
n
an
d
co
ns
ol
id
at
io
n
Fl
av
on
oi
d-
in
du
ce
d
im
pr
ov
em
en
ts
in
lea
rn
in
ga
nd
m
em
or
ym
ig
ht
in
vo
lve
up
re
gu
lat
io
n
of
PS
A-
N
CA
M
an
d
N
M
DA
-N
R2
B
[12
9]
10
-w
ee
k-
ol
d
C5
7B
L/
6J
fe
m
ale
m
ice
an
d
PN
D
19
m
ale
off
sp
rin
g
AL
A
or
AL
A-
de
f
G
es
ta
tio
n
an
d/
or
lac
ta
tio
n
AL
A
du
rin
gg
es
ta
tio
n
+
lac
ta
tio
n
↑cellpro
lif
er
at
io
n
an
d
ne
ur
on
al
di
ffe
re
nt
iat
io
n
in
th
eD
G
of
PN
D
19
;A
LA
-d
ef
↑apopto
sis
N
/A
AL
A
is
re
qu
ire
d
in
bo
th
fe
ta
l
an
d
po
stn
at
al
sta
ge
sf
or
en
ha
nc
ed
AH
N
in
off
sp
rin
g
[17
7]
Eff
ec
ts
of
di
ffe
re
nt
pr
on
eu
ra
lp
las
tic
ity
di
et
ar
yi
nt
er
ve
nt
io
ns
(C
R,
IF
,a
nd
po
lyp
he
no
lic
/fa
tty
ac
id
su
pp
lem
en
ta
tio
n)
on
br
ain
fu
nc
tio
n
an
d
co
gn
iti
on
in
re
ce
nt
an
im
al
stu
di
es
(2
01
0
on
wa
rd
s)
.A
DX
:a
dr
en
ale
ct
om
y;
AL
A:
훼-linole
ni
ca
cid
;B
CK
O
:b
ra
in
CR
EB
kn
oc
ko
ut
m
ice
;B
D
N
F:
br
ain
-d
er
iv
ed
ne
ur
ot
ro
ph
ic
fa
ct
or
;C
G
RP
:c
alc
ito
ni
n
ge
ne
-r
ela
te
dp
ep
tid
e;
CO
RT
:c
or
tic
os
te
ro
ne
;C
R:
ca
lo
rie
re
str
ict
io
n;
CR
EB
:c
AM
P
re
sp
on
siv
e-
ele
m
en
tb
in
di
ng
;C
SA
:c
on
tin
uo
us
sp
on
ta
ne
ou
sa
lte
rn
at
io
n
ta
sk
;D
G
:d
en
ta
te
gy
ru
s;
EP
A-
E:
et
hy
le
ico
sa
pe
nt
ae
no
ic
ac
id
;E
RK
1/2
:e
xt
ra
ce
llu
lar
sig
na
l-r
ela
te
d
ki
na
se
1/2
;E
X:
ex
er
cis
et
ra
in
in
g;
G
I:
ga
str
oi
nt
es
tin
al
tra
ct
;I
F:
in
te
rm
itt
en
tf
as
tin
g;
IG
F-
I:
in
su
lin
-li
ke
gr
ow
th
fa
ct
or
-I;
KA
:k
ain
ic
ac
id
;L
D
:l
on
gd
ay
;L
TP
:l
on
g-
te
rm
po
te
nt
iat
io
n;
m
BD
N
F:
m
at
ur
ef
or
m
of
BD
N
F;
M
DA
:m
alo
nd
ia
ld
eh
yd
e;
M
W
M
:M
or
ris
wa
te
rm
az
e;
N
/A
:n
ot
as
se
ss
ed
;N
M
DA
R:
N
-m
et
hy
l-D
-a
sp
ar
ta
te
re
ce
pt
or
;p
-C
RE
B:
ph
os
ph
or
yl
at
ed
CR
EB
;p
ro
BD
N
F:
pr
ec
ur
so
rf
or
m
of
BD
N
F;
PS
A-
N
CA
M
:p
ol
ys
ia
ly
lat
ed
ne
ur
al
ce
ll
ad
he
sio
n
m
ol
ec
ul
e;
RE
S:
re
sv
er
at
ro
l;S
D
:
sh
or
td
ay
;S
H
RS
P:
str
ok
e-
pr
on
es
po
nt
an
eo
us
ly
hy
pe
rte
ns
iv
er
at
s.
Neural Plasticity 5
Whilst BDNF is a well-establishedmolecule implicated in
brain plasticity, no consensus exists regarding the upregula-
tion of BDNF by CR. Whilst some argue in its favor [50, 51],
others could not verify such an effect [52], a phenomenon
that could be due to differences in the models used (aging,
stroke, obesity, and others) and/or the duration and intensity
of CR. In addition, when exercise training in conjunction
with CR was applied to hypertensive rats, a synergistic
effect between the two environmental interventions led to
prevention of cognitive decline and upregulation of BDNF
[51]. This suggests that the combination of CR with other
positive inducers of brain plasticity, in this case exercise
training, may provide more effective strategies to prevent
cognitive decline [51].
2.3. Impact of CR on Mood/Anxiety. As discussed below in
Sections 2.4.2 and 2.5.2, the majority of studies on the effects
of CR in humans focused on the elderly population. For this
reason, the findings reported in this section refer to animal
studies only.
Depression/Anxiety and Brain Plasticity. Although very often
reported as comorbid, depression and anxiety disorders are
classified as distinct categories of neuropsychiatric illness.
Depression is a mood disorder, along with bipolar disorder.
It is a chronic illness characterized by persistent feelings of
sadness and loss of interest in previously enjoyed activities
[53]. In animal models, depressive-like behavior has been
associated with decreased levels of AHN [14, 54]. In addition,
in both animal and humans, depressive phenotypes have
been consistently associated with altered levels of BDNF,
suggesting that neural plasticity is significantly affected in
the depressed brain. Before we discuss these data, we first
describe depression and anxiety in context of different mark-
ers of brain plasticity.
Anxiety disorders are characterized by intense fear and
autonomic responses to perceived or real threats. Neuroimag-
ing studies have revealed that an extensive network of brain
circuits is implicated in the generation of overexaggerated
responses to potentially dangerous stimuli [55, 56]. At the
cellular and molecular levels, decreased levels of AHN [17]
and altered levels of BDNF [56] have also been associated
with increased anxiety and may possibly account for their
high comorbid prevalencewith depressive disorders. Encour-
agingly, different dietary interventions hold the promising
ability to reverse these changes in markers of brain plasticity
[57].
2.3.1. Animal Studies. Table 2 outlines recent animal studies
on the effects of CR over mood/anxiety. Interesting findings
in rodents were recently presented by Riddle et al. [58].
In their study, female adolescent mice and adults of both
sexes that underwent 60% CR for only 7 days exhibited
enhanced fear extinction learning and retention, a process
normally impaired in patients with anxiety disorders [59]
and which requires active neural plasticity [60]. Further
to this, the effects observed in the CR mice could not
be observed in age-matched serotonin transporter (SERT)
knockout mice, suggesting that CR facilitates improved fear
extinction through mechanisms that are SERT dependent
[58]. In contrast, another study of lifelong 60% CR led to
anxiogenic, rather than anxiolytic, effects [47]. Similarly, 50%
CR when applied to young rats (starting at postnatal day
28 for 5 weeks) led to increased depression- and anxiety-
like behaviors, whichwere accompanied by decreased expres-
sion of serotonin reuptake transporter [61]. This divergence
among animal studies investigating the impact of CR on
mood and anxiety could be due to differences not only in the
duration of the dietary intervention, but also in the age and
strain of animals. These incongruences highlight the need
for further studies investigating the ideal contexts where CR
could lead to promental health effects.
Lutter and colleagues report that the hypothalamic orex-
igenic hormone ghrelin has a major defensive role against
depressive-like symptoms associated with chronic stress [62].
Consistently, 10 days of CR enhanced the activation of orexin
cells after social defeat and reversed the behavioral deficits
seen inwild-typemice submitted to the social defeatmodel of
chronic stress [63].This reversal was not observed in orexin
knockoutmice, revealing an additional candidatemechanism
through which CR exerts its anxiolytic and antidepressant
effects [63]. In contrast, exposure to moderate CR for 3weeks
led to an increased stress response [64]. Moreover, transition
from CR to high-fat diet led to increased binge eating, an
undesirable and stress-related outcome likely mediated by a
CR-induced reprogramming of orexinergic pathways [64].
Together these results not only indicate that orexinergic
pathways are another mechanism engaged by CR, but also
point for the need of further studies addressing how the
duration and maintenance of CR, as well as regulation of
orexin and stress, may interact so that interventions can be
designed towards optimal results for plasticity and mental
health.
2.4. Impact of CR on Aging
The Aging Brain and Brain Plasticity. The aging brain is
characterized by functional andmetabolic changes, including
an increased vulnerability to insults and disease [41]. These
changes underlie the neuronal dysfunction associated with
the cardinal feature of aging and cognitive decline, epito-
mized by impaired performance on tasks dependent on the
hippocampus and associated networks [65, 66].
It is increasingly appreciated that severe neuronal loss
does not drive age-related cognitive impairment but rather
aging is characterized by numerous functional and structural
alterations that together impair brain plasticity [65], such as
a decrease in synaptic plasticity as evidenced by reduction
in the ability of aged rats to sustain LTP [67]. Both levels
of BDNF and its receptor TrkB decrease with age and these
reductions correlate with impaired memory and dendritic
spine density among hippocampal neurons [68]. In addition,
AHN markedly declines with age and aging has also been
reported to be a major contributor to the reduced prolifer-
ation of NSCs [66].
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2.4.1. Animal Studies. Table 3 outlines recent animal studies
that have evaluated the effect of CR on brain plasticity in the
context of aging.
Maintaining rodents on CR regimens prevents age-
related declines in learning and preserves spatial andworking
memory [69, 70]. In addition, it is not only lifelong CR
that exerts positive effects in combating age-related processes
but also starting CR in midlife [71] or short exposures
even at a late age [72–74] also entails beneficial effects.
One of the mechanisms possibly underlying these effects
is through maintaining the levels of NMDA receptors in
the hippocampus, normally subject to reductions with age
[44]. Preservation of these receptors enables reversal of age-
related declines in LTP [75]. Many studies have reported that
CR attenuates age-related declines in the levels of synaptic
proteins [44, 76] particularly in the CA3 subregion of the
hippocampus [44].
Mladenovic Djordjevic and colleagues demonstrate that
lifelong CR enhances synaptic remodelling as evidenced by
reversal of age-related declines in the expression of the presy-
naptic proteins synaptophysin, GAP-43, and 훼-synuclein in
the hippocampus and cortex of rats [76]. CR also increases
adult neurogenesis in young adult rats [77] and reverses
age-related decline in neurogenic activity and significantly
enhances survival of newborn glial cells in the DG in older
mice [78, 79].
Another mediator of neural plasticity is neuropeptide
Y, known not only for its function on the regulation of
ingestive behavior [80], but also for its interaction with the
cholinergic system for improved learning and memory [81],
as well as for promoting hippocampal neurogenesis [82].
Recently, it has been reported that long-term 40% CR had
multiple effects on the densities of neuropeptide Y receptor
subtype densities throughout the brain [83]. For example,
CR induced decreases in Y1-receptor density in the DG and
reversed age-related declines in neuropeptide Y2-receptor
density inCA2 subfield.These data lead the authors to suggest
that long-term CR may exert specific effects of its own, in
addition to combating age-related changes. In turn, changes
in neuropeptide-Y-mediated signalling may impact brain
circuits that regulate cognition and emotion [83].
2.4.2. Human Studies. Whilst not conducted in an aging
cohort, the National Institute of Aging CALARIE (Com-
prehensive Assessment of Long-Term Effects of Reducing
Intake of Energy) study examined the effect of 6-month CR
and CR in combination with physical exercise on cognitive
function (푛 = 48; BMI: 25–30; age range: 25–50 yrs) [84].
A comprehensive array of cognitive tests of verbal memory,
visual memory, and attention were conducted at baseline and
at 3 and 6 months following intervention. During the trial,
no improvements, but equally no deficits, emerged across
these cognitive measures.These disappointing findings must
be considered in context of a small sample size and limited
statistical power.
The ENCORE (Exercise and Nutrition Interventions
for Cardiovascular Health) study involved 124 participants
(mean age: 52 ± 9 years) with elevated blood pressure, seden-
tary lifestyles, and a body mass index (BMI) greater than
25 [85]. Individuals adhering to antihypersensitive treatment
combined with CR and exercise demonstrated significant
improvements in both executive-function memory learning
and psychomotor speed when evaluated at 4months follow-
ing intervention. The potentially synergistically interaction
between CR, weight loss, and aerobic fitness likely underlies
the neurocognitive improvements observed.
Witte and colleagues [234] report that adherence to a
daily 30% CR regimen in a cohort of 50 healthy elderly
subjects (mean age: 60.5 years; mean BMI: 28) improved
performance on memory tests versus both a group with
increased intake of PUFAs and the control AL group. In
particular, verbal memory scores improved with a mean
increase of 20% after 3 months of intervention in the CR
group. Notably, the levels of BDNF did not change in the
CR and PUFA groups. This is the first study to demonstrate
the beneficial effects of CR on memory performance in an
aged cohort.The negative BDNF finding does not definitively
reflect an absence of BDNF involvement in mediating the
effects of CR, as its levels may be altered in closer proximity
to the start of the intervention or perhaps be revealed when
related to other parameters such as neuroimaging [87]. In
addition, whilst increased serum levels of BDNF have been
linked to increased hippocampal volume and improved spa-
tial memory in humans, even when controlling for variation
due to aging [88], suggesting that circulating levels of BDNF
may reflect levels of BDNF produced by the brain, BDNF
is also produced by peripheral cells, tissues, and organs
[89, 90]. As such, it remains an open question as to how
accurately blood levels of BDNF reflect brain BDNF and its
posited effects upon plasticity. Future studies should address
longitudinal alterations in the levels of BDNF and other
neurotrophins during the course of the CR intervention.
2.5. Impact of CR on AD
Alzheimer’s Disease (AD) and Brain Plasticity. AD is an age-
related and debilitating neurodegenerative condition epit-
omized by impoverished learning, memory, and executive
function [91].The pathognomonic features of AD include (1)
the buildup of extracellular 훽 protein (derived from cleavage
of the amyloid precursor protein (APP) into diffuse plaques
and (2) intranuclear aggregation of hyperphosphorylated
forms of the microtubule and structural tau protein into
neurofibrillary tangles [92].
Synapses are particularly vulnerable to impairment and
irreversible damage upon exposure to 훽-amyloid and the
synaptic formation is regarded as a key site in the initia-
tion of the neurodegenerative process [93]. Human studies
have reported compromised levels of BDNF and associated
signaling in the preclinical stages of the disease and at
postmortem [94, 95]. Alterations in the levels of hippocampal
neurogenesis are increasingly regarded as an integral aspect
of AD [96]. Notably, the putative role of nutrition in both
contributing to and mitigating cognitive impairment in AD
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has emerged as a topic of increasing scientific and public
interest [97–99].
2.5.1. Animal Studies. Wu and coworkers report that 30%
CR for 4 months in the transgenic mouse model of AD
had profound effects on the pathophysiology of the disease,
attenuating ventricle enlargement, hippocampal atrophy, and
caspase-3 activation, as well as decreasing reactive gliosis and
tau phosphorylation [100]. Moreover, upregulation of genes
associated with neurogenesis and synaptic plasticity was
found in the CR hippocampus, along with downregulation
of genes associated with the expression of inflammatory
markers. The combined modulation of disease pathology
and enhancement of hippocampal neurogenesis by CR likely
underlie amelioration of memory deficits as assessed by the
novel object recognition and contextual fear paradigms in
this study.
2.5.2. Human Studies. The beneficial effects of CR on trans-
genic models of AD are consistent with epidemiological
studies that report that high caloric diets are associated
with an increased risk of developing AD [79]. For example,
Luchsinger et al. observed that among those individuals in
the Washington Heights-Inwood Columbia Aging Project
cohort, a higher intake of calories and fats, the risk of
developing ADwasmarkedly elevated but only in individuals
carrying the ApoE4 allele, a major genetic risk factor for AD
[101]. In support of this, epidemiological studies reveal that
those who habitually consume fewer calories have a reduced
risk of developing AD (Gustafson et al.) [102]. In a recent
population-based case-control study, Geda and coworkers
report that a high calorific intake is associated with near
twofold increase in risk of having mild-cognitive impairment
[103].
3. Intermittent Fasting: Effects of Expanding
Time between Meals
3.1. Background and Physiological/Molecular Mechanisms of
IF. Intermediate or intermittent fasting (IF) refers to alter-
nate periods of AL intake with complete or partial restric-
tion of calories. Similar to CR, IF does not mean severe
nutrient deprivation/starvation and all IF regimens are on a
background of adequate vitamin and mineral intake [104]. IF
has recently seen a surge in popularity through the advent
of the “5,2” diet, which involves two days of complete or
partial CR during a weekly period [105]. Importantly, IF does
not necessarily reduce overall caloric consumption or lower
bodyweight, since subjects may compensate for reduced
intake during the restriction period by overeating on the AL
phase, although in many studies implementation of IF results
in a 20–30% reduction in caloric consumption over time
[33, 35].
IF regimens have been demonstrated to induce a mul-
titude of positive impacts on age-related diseases in animal
studies, including the attenuation or prevention of diabetes-
like phenotypes and cardiovascular disease, as well as increas-
ing maximal lifespan [33].
At the molecular level, IF is thought to engage adaptive
cellular stress response pathways and appears to engagemany
of the pathways described above for CR [38, 68].
3.2. Impact of IF on Brain Plasticity. The growing popularity
of IF regimens among human subjects is supported by
evidence that IF induces beneficial changes in animal studies;
notably, many studies suggest that IF results in enhancement
of brain plasticity and at cellular and molecular level with
concomitant improvements in behavior (Table 1).
Maintaining rats on an IF regimen increased the resis-
tance of hippocampal neurons to chemically induced degen-
eration [106, 107] and in experimental models of stroke [50].
Moreover, the neuroprotective effect of IF is also associated
with preservation in learning and memory performance
[50, 79]. Furthermore, the effects of IF following excitotoxic
challenge associate with lower levels of corticosterone, lead-
ing not only to decreased hippocampal cell death, but also
to increased levels of hippocampal BDNF and pCREB and
reversal of learning deficits [107].
Increased survival of newly born cells in theDG, resulting
in enhanced neurogenesis and gliogenesis, has also been
reported as an effect of IF feeding in mice [108], as well as
increased LTP and expression of the NMDA receptor subunit
NR2B, resulting in enhanced learning [109].
Interestingly, IF but not CR for 20 weeks increases
the resilience of hippocampal neurons to excitotoxic stress,
suggesting distinct neuroprotective effects of IF [110].
3.3. Impact of IF on Mood/Anxiety. To our knowledge, no
intervention or epidemiological study of the effects of IF
on mood/anxiety in the human population has taken place;
for this reason, we will focus this section on the promising
findings from animal research (Table 2).
Whilst the majority of studies on the effects of fasting
applied chronic protocols, a few have also investigated the
outcomes of acute interventions. In this respect, a recent
study has shown that 9 h fasting in mice leads to significant
antidepressant effects [111]. Interestingly, additive effects were
observed when the antidepressant drug imipramine was
administered in conjunction with the fasting period. As
proposed by the authors, these findings could be the start of a
translation of acute fasting in conjunctionwith imipramine as
a low-cost strategy to potentiate antidepressant effects in clin-
ical practice. Furthermore, acute fasting led to an increase of
the p-CREB/CREB ratio (p-CREB: phosphorylated CREB), a
biological effect that is consistent with what has been found
by some CR studies [46].
3.4. Impact of IF on Aging
3.4.1. Animal Studies. Recent animal studies on the effects of
IF upon aging are described in Table 3. Singh and coworkers
aimed to test whether short-term late-onset exposure to an
IF regimen could improve age-related declines in cognitive
and motor functions, in association with possible changes
in the expression of plasticity markers [112]. Old IF rats
exhibited enhanced memory. Furthermore, these authors
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also evaluated Ca2+ signaling, a key regulator of synaptic
plasticity, following short-term IF. In particular, they assessed
the expression of serine/threonine protein phosphatase cal-
cineurin (CaN), known for mediating the effects of Ca2+
signaling on synaptic plasticity, cell survival, and ultimately
cognition [113], as well as the Ca2+-dependent protein kinase
(CaM kinase), which plays a key role in synapse formation
and neurotransmitter release, thus influencing neuroplastic-
ity, learning, and memory [114, 115]. Notably, the expression
of CaN and synaptophysin, which are known to significantly
decrease with age in the CA3 and DG subregions of the
hippocampus, was partially restored by the short-term IF and
suggests recovery of loss of synapse density and concomitant
increases in neurotransmission [112]. Given that IF decreased
CaN levels and increased CaM expression in the hippocam-
pus of aged rats, the potential beneficial effect of IF regimen
on learning and memory likely involves the expression of
synaptic proteins regulating calcium homeostasis [112].
Similarly, Mladenovic Djordjevic et al. report that IF
induced elevated synaptophysin expression in the DG and
CA3 [76].These findings are supported by the similar effects
of CR in mitigating age-related declines in synaptophysin
levels [44, 116], suggesting that reduced levels of hippocampus
stress, enhanced synaptic plasticity, and increased neuro-
genesis underlie the preservation of synaptic functionality
associated with CR and IF regimens. IF has also been to
shown to reverse the age-related impairments in the neuronal
plasticity marker neural cell adhesion molecule (NCAM)
[73].
3.4.2. Human Studies. The aforementioned CALARIE study
as well as studies in the cardiology field has provided proof
of principle that dietary interventions based on reducing
energy intake are not only safely tolerated by humans, but also
elicit beneficial effects on a myriad of general health markers
including insulin sensitivity, markers of oxidative stress,
hypertension, and inflammation (see Weiss and Fontana,
2011, for a detailed review [40]).
Historically, a study by Vallejo later reanalyzed by
Stunkard demonstrated that IF increased measures of
healthspan and lifespan, proving its feasibility in human
subjects [117, 118]. In support of these studies, Heilbronn
and coworkers demonstrated that a 22-day IF regimen in a
study of 16 nonobese humans (age range: 23–53) improved
scores in the respiratory quotient, fat oxidation, and insulin
sensitivity [119]. Together, these results suggest that IF is
a feasible intervention in humans and is associated with
beneficial effects in the metabolic profile; however, it is
unlikely that such a regimen could be satisfactorily tolerated
over a prolonged period owing to likely increase in aversive
subjective states on the “off ” day.The authorsmake a practical
suggestion that the addition of a small meal on the fasting day
improve the tolerability and adherence to IF.
In a recent study of 32 aged Malaysian men (age: 59.7 ±6.3; BMI: 27), adherence to an approximate 25% CR diet in
conjunction with two days/week of religious fasting resulted
in marked reductions in scores on tests of tension, anger,
confusion, and depression [120].These positive changes upon
affect occurred in conjunction with small reductions in
weight, BMI, and percent body fat and support previous
data from this group in a similar sized cohort where this
same dietary intervention reduced scores on measures of
depression [121].
It would be of great interest to further investigate the
elicited effects of IF in a human study on measures of cog-
nition, mood, and anxiety in conjunction with physiological
markers of brain plasticity.
3.5. Impact of IF on AD. To our knowledge, no studies on
the impact of IF upon AD date have been conducted with
human subjects. As such, the findings discussed herein were
generated from animal studies (Table 3).
Halagappa and colleagues utilized a triple transgenicmice
model of AD, reporting that long-term maintenance of these
mice (14 months) on either a 40% CR or IF diet, prior
to the onset of the disease phenotype, rescued cognitive
deficits [122]. The beneficial effects of CR on cognition were
associated with significantly reduced levels of 훽-amyloid
protein and phospho-tau. Intriguingly, IF appeared to protect
neurons from injury despite the fact that there are no
reductions in either A훽 or Tau, suggesting that this dietary
approach may protect neurons downstream of A훽 and tau
aggregation. Further to this, extensive 훽-amyloid deposition
has been well documented in elderly persons in the absence
of cognitive deficits [123]. Together, these data suggest that
stimulation of adaptive stress responses is a possible mecha-
nism by which cognition is preserved despite marked signs of
disease pathology [43].
4. Dietary Content: Focus on Polyphenols as
Potent Food-Derived Plasticity Inducers
4.1. Background and Physiological/Molecular Mechanisms of
Polyphenols. Polyphenols are the most abundant antioxi-
dants in the human diet and are present in a wide variety
of fruits, teas, and consumed plants, including cocoa [124].
Besides their antioxidant action, polyphenols have been
shown to enhance neuronal function aswell as stimulate cere-
bral blood flow and neurogenesis [125]. Curcuminoids and
flavonoids represent two of the main subtypes of polyphenols
demonstrated to act upon brain function at the cellular
and molecular level [124]. Curcumin, the most ubiquitous
curcuminoid and active ingredient in the spice turmeric,
has been consumed for medicinal purposes for thousands of
years [126]. A distinctive feature of curcumin is the ability to
modulate a multitude of signaling molecules and its varied
properties, including being antibacterial, anti-inflammatory,
chemotherapeutic, and neuroprotective [126].
Resveratrol is another naturally occurring polyphenol
found in the skin of red grapes, nuts, and several other plants
which has been extensively researched owing to its neuro-
protective effects on the brain [86]. Resveratrol is a mimetic
of CR, extending the maximal lifespan in yeast, worms,
flies, and fish. In particular, both CR and resveratrol trigger
overexpression of SIRT1, a NAD-dependent class III histone
deacetylase that participate in transcriptional silencing of
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genes including those implicated in cell cycle regulation and
lifespan extension [86]. The precise mechanisms underlying
the neuroprotective role of resveratrol remain to be fully
elucidated but it is likely that these beneficial effects result
from a synergy of their antioxidant properties and SIRT1
activating capability [86].
Due to their well-documented effects on neural plasticity
as well as upon cognition, mood/anxiety, and aging, this
sectionwill focus onfindings from studieswith curcumin and
resveratrol.
4.2. Impact of Polyphenols on Brain Plasticity. In addition to
their antioxidant properties, polyphenols have been reported
to exert neuroprotective effects by directly modulating cellu-
lar pathways related to neuronal processes and synaptic plas-
ticity (Table 1). In rodents, these include those that converge
on the aforementioned CREB, a pivotal transcription factor
linked to the expression of BDNF [127, 128], and other hip-
pocampal plasticity related markers such as the expression of
BDNF itself [128], glutamatergic receptors subunits (NMDA-
NR2B), and polysialated neural cell adhesionmolecule (PSA-
NCAM: a marker of developing and migrating neurons)
[129].
The classic activation of SIRT1 by resveratrol has been
consistently demonstrated and to it novel players have been
added which impact brain plasticity, such as the reduced
expression of microRNAs miR-134 and miR-124 leading to
upregulation of CREB levels and subsequently promotion of
BDNF synthesis in the hippocampus [130]. However, SIRT-1
activation has also been suggested to negatively regulate
neuronal differentiation in the adult hippocampus [131],
suggesting other targets throughwhich resveratrolmight also
trigger proplasticity effects, at least in the context of AHN.
An interesting report has provided evidence for novel
insights on the mechanistic loop through which resveratrol
might exert its effects on neural plasticity and, thereby,
on cognitive improvement. After hypothesizing that orally
administered resveratrol acts on the hippocampus through
stimulation of the gastrointestinal tract (GI) leading to
increased expression of insulin-like growth factor-I (IGF-I),
Harada et al. showed that the enhancing effects of resveratrol
on hippocampal angiogenesis, neurogenesis, and cognition
were absent in calcitonin gene-related peptide (CGRP)
knockout mice [132]. Sensory neurons of the mouse GI
have been shown to transmit information to the hippocam-
pus through the spinoparabrachial circuit, increasing the
hippocampal levels of CGRP, which in turn induce local
astrocytic production of IGF-I [133]. Given the abolishment
of resveratrol-induced effects in CGRP−/− mice, the authors
propose that sensory neuron stimulation by resveratrol in
the GI tract would lead to an increase of IGF-I production
in the hippocampus, with consequent enhancement of hip-
pocampal angiogenesis, neurogenesis, and, finally, cognitive
function [132].
Possible synergistic effects of different dietary inter-
ventions on brain plasticity represent a promising field
to translational neuropsychiatry. Interestingly, Dal-Pan and
colleagues showed that long-term 70% CR or resveratrol
supplementation for the same period (18 months) exerts
similar beneficial effects for cognition in adult primates [134].
Whether the effects of CR and IF could be enhanced or in
some contexts replaced by supplementationwith polyphenols
is thus an attractive field of research that could add to the
potential of dietary interventions.
4.3. Impact of Polyphenols on Mood/Anxiety. To our knowl-
edge, no functional studies on the impact of resveratrol
or curcumin in the context of mood/anxiety have been
conducted with human subjects; we therefore focus this
section on findings from animal studies (Table 2).
Growing, although not unanimous [135], evidence sug-
gests that the regular consumption of dietary polyphenols can
lead to positive effects on mental health-related behaviors, a
process probably involving brain plasticity [57].
The antidepressant effects of resveratrol have been con-
sistently proposed by a number of recent studies. Chronic
administration of resveratrol was able to prevent a wide range
of detrimental effects on cognition induced by the classic
unpredictable chronic mild stress model of depression [136],
including reduction in serum corticosterone levels, increased
levels of BDNF, phosphorylated extracellular signal-regulated
kinase (pERK) and pCREB in the prefrontal cortex and hip-
pocampus, and prevention of cognitive deficits [137]. Similar
biological measures were found in nonstressed mice admin-
istered with resveratrol, which also presented with reduced
depressive phenotype comparable with those of fluoxetine-
treated animals [138]. Resveratrol has also been proposed to
buffer prenatal stress in the adult offspring, likely through
protective mechanisms against oxidative stress [139] and, of
special relevance for neural plasticity, through enhancement
of hippocampal BDNF and postnatal neurogenesis levels
[140].
Interestingly, a number of studies point for a role of the
serotoninergic system in modulating hippocampal plasticity
in context of depression [141, 142]. Mice exposed to UCMS
but receiving polyphenols extracted from tea leaves (tea
polyphenols, TPs) daily from the 3rd week of stressors
onwards presented with normalized depression-related phe-
notype [143]. Besides reversing the UCMS-induced expres-
sion of oxidative stress markers, TP administration was also
capable of reversing the altered concentrations of serotonin
and noradrenaline in the prefrontal cortex and hippocampus.
Similarly, normalized levels of serotonin in the hippocam-
pus and, furthermore, inhibition of the serotonin degrad-
ing enzyme monoamine oxidase-A (MAO-A) activity after
UCMS exposure have also been shown to be biological effects
of treatment with trans-resveratrol [144].
4.4. Impact of Polyphenols on Aging
4.4.1. Animal Studies. Many different polyphenols have been
reported to retard age-related declines in CNS function,
cognition, and behaviour; recent reports in animal studies
are outlined in Table 3. For example, blueberries, which are
rich in anthocyanin and flavanols subset of polyphenols,
are effective in persevering spatial working memory in aged
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animals [125], a process likely mediated by the marked
increases in NSC proliferation in the DG of aged rats sup-
plemented with these berries [145]. More recently, Rendeiro
and coworkers report that dietary supplementation with
flavonoids improves spatial working memory in association
with increased expression of hippocampal BDNF [129].
Conboy et al. report that short-term (8 days) curcumin
supplementation to aged rats enhanced PSA-NCAM expres-
sion in the DG and markedly improved both spatial learning
and memory [146]. Dong et al. assessed the effects of 6-
and 12-week curcumin-supplemented diet on hippocampal
cellular proliferation, cognitive function, and transcriptional
responses in aged rats [147]. Only in 12-week treatment
did spatial memory improve, suggesting that prolonged
curcumin consumption is required to prevent or slow down
the decline of cognitive function with aging [147], contrary to
the benefits of short-term exposure reported by Conboy and
coworkers [146]. In addition, only the 12-week intervention
enhanced AHN, suggesting that, at the dosage of curcumin
used, the generation of new neuronal cells may require an
accumulated effect of the active metabolites over a prolonged
period [147].
Dong and colleagues provide further support for the
relationship between prolonged exposure and its effects on
brain plasticity, as evidenced by an exon array of hippocampal
and cortical rat tissue that revealed differentially expressed
genes with functions related to brain development, cognition,
and neurogenesis but dependent on the length of curcumin
treatment [147]. For example, expression of the NeuroD1
gene, integral for AHN and survival of neuronal progenitors
[148], was increased following 6-week curcumin treatment.
Additional genes altered by 6- and 12-week curcumin treat-
ment included Wnt2, Nnat, Tiam1, and Unc5d which have
diverse roles in neuron development. Further to this, 12-week
curcumin treatment markedly upregulated genes implicated
in synaptic transmission and memory formation, includ-
ing Adcyl, Kit, and LPL in the hippocampus and Shank3,
Cip98, Snip, and Nlgn2 in the cortex. Interestingly, it has
been suggested that a reduction in the expression level of
adenylyl cyclase I (Adcy1) in the hippocampus might greatly
contribute to age-related defects in spatial memory [149].
Together, these results suggest that the beneficial effects
of curcumin in improving cognition among aged rats are
possibly explained by the enhancement of AHN and synaptic
plasticity as facilitated by upregulation of development-
associated genes in the brain [147].
4.4.2. Human Studies. A number of epidemiological studies
have reported that increased consumption of a number of
different polyphenols improves various aspects of cognitive
function in the aging population [150].
Among a population-based cohort of nondemented
elderly Asian subjects (푛 = 1,010; mean age: 68.9 ± 6.8
years),multivariate analyses revealed that improved cognitive
function was associated with those who regularly consume
curry, and thus a large amount of the polyphenol curcumin,
when compared to those who never or rarely consumed curry
[151]. Similar results were reported in context of increased
dietary flavonoid intake [152].
The recent report of 13-year long clinical study builds
upon these findings by investigating the relationship between
specific classes of polyphenols and cognitive performance
in a cohort of 2574 middle-aged adults (age range: 35–
60 at baseline) [153]. Utilizing participant dietary records
regarding specific polyphenol consumption and a battery of
cognitive tests, multivariate models revealed that increased
intake of catechin, theaflavins, flavonols, and hydroxybenzoic
acids was particularly associated with improved episodic
memory and in some cases with preserved verbal memory.
It must be noted that unexpected negative associations were
also observed; for example, increased intake of the subclasses
catechins; proanthocyanidins and flavanols were linked to
poorer performance in tests of executive function. Whilst
no mechanistic studies account for this negative association,
it has been suggested that, under certain conditions, some
catechins may exert multiple effects on the brain includ-
ing a prooxidant action [154]. Nevertheless, together these
encouraging studies build upon the molecular and cellular
mechanistics reports conducted in animals to highlight the
strong potential of dietary polyphenol intake to support
preserved cognitive performance in the elderly population.
4.5. Impact of Polyphenols on AD
4.5.1. Animal Studies. Polyphenols derived from multiple
dietary sources are able to counteract cognitive deterioration
and reduce neuropathology in different animal models of
AD [155]. Recent animal studies also support a role for these
compounds in promoting brain plasticity in context of AD
(Table 3). For example, Dong and coworkers additionally
report that 12-week curcumin treatment of aged rats resulted
in markedly differential expression of genes thought to
participate in both the AD neurodegenerative process and
synaptic plasticity [147], such as the Cav1 gene implicated in
alterations of cholesterol distribution in the AD brain [156],
spatial memory formation [157], and age-related working
memory decline [158].
Some interesting results were also generated by studies
using a grape-derived polyphenolic preparation (GP), a
mixture of proanthocyanidins (PACs), comprising catechin
(C), epicatechin (EC), catechin gallate, and epicatechin gal-
late [159]. The potential therapeutic benefits gleamed from
natural compounds containing GP and PAC are hindered
by limited knowledge with regard to their metabolism and
whether sufficient levels of these metabolites enter to brain to
exert their effects [159]. Wang and coworkers aimed to bridge
this knowledge gap by utilizing biosynthetic brain-targeted
PAC metabolites and studying their pharmacokinetics in
relation to their therapeutic effects upon cognitive deterio-
ration in a transgenic mouse model of AD [159]. Animals
were treated for 5 months starting at 7 months of age with
different formulations of GP prior to the development of AD
neuropathology and cognitive deficits. All three formulations
were demonstrated to interfere with the initial protein-
protein interaction ofA훽1–40 andA훽1–42, but onlymonomeric
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GP reduced the content of toxic oligomeric A훽 species
and improved spatial memory retention. Of special note,
the authors reported that the monomeric metabolite 3耠-푂-
Me-EC-Gluc significantly increased the phosphorylation of
CREB at differential sites.This study reveals for the first time
that a brain-targeted metabolite derived from a polyphenol
is capable of restoring synaptic plasticity in the AD-afflicted
hippocampal formation.
Similarly, a recent study by Ho and colleagues evaluated
the accumulation of polyphenol metabolites in the mouse
brain of an AD-transgenic model following oral dosage with
a Cabernet Sauvignon red wine (abundant in resveratrol)
[160]. Using a dose that is equivalent to moderate daily
wine consumption in humans, they report that one of the
Cabernet Sauvignon brain-targeted metabolites, quercetin-
3-0-glucuronide, reduced neuronal generation of 훽-amyloid
peptides and prevented the formation of the toxic oligomeric
species of this peptide [160]. Moreover, treatment with this
metabolite markedly reversed AD-type deficits in hippocam-
pal basal synaptic transmission and LTP, via a mechanism
possibly dependent on activation of signaling pathways that
result in phosphorylation of CREB.
Recent data from Hoppe et al. adds to the discussion
of the neuroplasticity molecules possibly underlying the
behavioral effects of polyphenols in context of AD [161].
Rats treated intraperitoneally with free or nanoencapsulated
curcumin for 10 days did not show 훽-amyloid-induced
cognitive impairment or typical decreases in both hippocam-
pal synaptophysin and BDNF levels. Of special note, for
future application in clinical practice, the nanoencapsulated
curcumin administration was able to produce effects in a 20-
fold lower dose, showing the potential of this technology for
drug delivery to CNS targets.
The studies described above reveal for the first time
that brain-targeted metabolite derived from polyphenols
is capable of entering the brain, positively modifying AD
neuropathology and is able to restore synaptic plasticity in the
hippocampal formation and as such offers great potential as
a novel therapeutic agent.
4.5.2. Human Studies. A number of epidemiological studies
have reported that increased consumption of a number
of different polyphenols reduces the incidence and delays
progression of AD [150]. For example, just as increased intake
of the polyphenol curcumin improves cognitive performance
in the Indian elderly population [151], it has been suggested
that the low incidence of AD in this country is perhaps,
in part, also attributable to the increased consumption of
curcumin among its elderly population [127]. Similarly, a
cross-sectional study of 1003 Japanese individuals over the age
of 70 revealed that the consumption of more than or equal
to 2 cups of green tea per day was associated with over a
50%reduction in cognitive deficit [162]. Several epidemiolog-
ical studies have also indicated that moderate consumption
of red wine is associated with a lower incidence of AD
[163, 164].
There is a paucity of prospective clinical studies and
trials investigating the therapeutic potential of polyphenols
in AD [155]. However, results from the GuidAge study, a
prospective prevention study on the impact of the Ginkgo
biloba extract Egb761 on the conversion of elderly persons
(푛 = 2854, age: 70 years and older at baseline) with
memory complaints to AD, were recently reported [165, 166].
In this randomized control trial participants were required
to twice daily consume a 120mg dose of Egb761 for 5
years [166]. Disappointingly, long-term use of the polyphenol
extract Egb761 did not reduce the risk of progression to AD
when compared to placebo [166]. The authors noted that
the number of dementia-related events in their study was
much lower than expected resulting in reduced statistical
power to detect any effect. Indeed, overrecruitment of healthy
volunteers is a problematic issue in prevention trials, particu-
larly in dementia research where baseline control individuals
appear healthier and better educated than the general elderly
population [167].
Despite the disappointing results from the clinical trial of
theGinkgo biloba extract, which can plausibly be explained by
confounding factors, epidemiological studies clearly support
the promising preclinical work implicating increased con-
sumption of polyphenols in improved cognitive performance
and lower incidence of AD.
5. Dietary Content: Focus on n-3 Fatty Acids as
Potent Food-Derived Plasticity Inducers
5.1. Background and Physiological/Molecular Mechanisms of
PUFA. Positive effects on brain health and function have
also been shown as an outcome of PUFA-enriched diets
as well as for those with high levels of fish and nut oils.
Long chain essential PUFA, notably the omega-3 (n-3) fatty
acids docosahexaenoic acid (DHA) and eicosapentaenoic
acid (EPA), are fundamental to CNS function, considering
the lipid-rich nature of the brain [168].
Omega-3 fatty acids are classified as essential, meaning
that their levels depend on dietary intake, although their final
functional availability also depends on other factors regulat-
ingmetabolic events, such as polymorphisms of genes coding
enzymes that convert short-chain to long-chain PUFAs [169].
Although fish is the major source of the EPA and DHA
consumed (71%), these fatty acids are also contained in other
foods, such as meat (20%), eggs (6%), and plant foods (such
as leek and cereal-based products; 3%) [170].
The n-3 fatty acid DHA is an important structural
component of neural cell membranes and is, thus, essential
to appropriate neuronal functioning [171]. In particular, n-3
fatty acids can modulate cholesterol-induced reductions
in membrane fluidity by displacing cholesterol from the
plasmamembrane [124].This displacement leads to increased
membrane fluidity, increased number of receptors, enhanced
receptor binding and affinity, better ion channel functionality,
and modulation of gene expression of proteins involved
in signal transduction processes [172–175]. Together, these
effects lead to improved neurotransmission and signaling
and, therefore, to optimal cognitive functioning.
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5.2. Impact of PUFAs on Brain Plasticity. Fatty acids have
been implicated in enhancing brain plasticity and cognitive
function in healthy, adult rodents (Table 1).
It has been shown that, in hippocampal slices of rats
treated with EPA, LTP is significantly enhanced in CA1
neurons when compared with EPA-deficient hippocampal
slices [176]. In addition, this same study showed that EPA
applied in vitro was capable of decreasing cell death.
PUFA supplementation has also been associated with
enhancement of AHN [178, 179], which could be one of the
mechanisms underlying associated improvements in cogni-
tion and mood [180]. For instance, dietary supplementation
with n-3 PUFAs restored neurogenic markers in the DG of a
mouse model of systemic lupus erythematosus and Sjo¨gren’s
syndrome, characterised by lower levels of AHN among
other biological deficits [181]. Perinatal supplementation with
n-3 PUFA also mitigated the impairment in working and
short-term memory and altered fear response observed in
rats as a consequence of sevoflurane-induced neurotoxicity,
likely through decreased apoptosis and enhancement of hip-
pocampal cell proliferation [182]. Perinatal supplementation
with the DHA precursor 훼-linolenic acid (ALA) revealed a
consistent improvement of hippocampal neurogenesis in the
offspring, but only when the dam had been exposed to the
enriched diet also during pregnancy [177], highlighting the
importance of the appropriate timings of dietary interven-
tions for maximized results.
5.3. Impact of PUFA on Mood/Anxiety
5.3.1. Animal Studies. Recent studies focusing on the effects
of PUFA on mood/anxiety in animals are presented in
Table 2.
Rats exposed to an n-3-deficient diet during the gesta-
tional period and lactation presented with decreased brain
levels of DHA and plasticity markers, such as BDNF and
reduced activation of CREB in adulthood [184]. At the behav-
ioral level, these animals exhibited increased anxiety-related
phenotypes. Interestingly, similar biological changes but with
additional decreases in expression of other plasticity markers
such as GAP-43, Ca2+/calmodulin-dependent protein kinase
II (p-CAMKii), and phospho-synapsin have been observed in
rats initiallymaintained onn-3 fatty acid-rich diets during the
gestational period until postnatal week 12, when a transition
to a high-fat diet (low in n-3 fatty acids) was introduced [187].
Using a similar approach of switching rats from a PUFA-
enriched or deficient diet to a western-like diet (WD) with
higher percentage of fat and carbohydrates during the period
of brain maturation, Tyagi et al. report increased anxiety-
like behavior and decreased expression of the anxiety-related
NPY-1 receptor, along with disruption of BDNF signaling
in the frontal cortex of rats after mild traumatic brain
injury (mTBI) [188]. mTBI is an established important risk
factor for the development of psychiatric conditions such as
posttraumatic stress disorder (PTSD); these results highlight
the potential of healthy nutritional habits to counteract the
lowered threshold for the onset of neuropsychiatric illness
following mTBI. Indeed, n-3 fatty acid supplementation in
rodents as a means to improve AHN is under analysis for the
prevention of accidental injury-related PTSD [189].
A recent study further reinforces the idea that n-3
deficiency in rats might contribute to vulnerability to
stress [186]. Conversely, increased levels of hippocampal
BDNF associated with serotoninergic neurotransmission and
antidepressant effects have also been observed in rats exposed
to higher intake of fish oils [185].
5.3.2. Human Studies. The potential antidepressant action
of PUFA has been suggested to be true not only in animal
studies, but also in human subjects [190–192].
Frequent fish consumption (and, in some cases, seafood
intake as a whole) has been associated with decreased risk of
depression and suicidal ideation [193], higher self-reported
mental health status [194], and decreased prevalence of post-
partum depression [195]. Moreover, the low concentrations
of n-3 fatty acids in the blood of depressed patients [196, 197]
also support the potential role of altered levels of PUFA in the
development of depression. Furthermore, in patients diag-
nosed with unipolar depression, EPA treatment decreased
symptoms of depression to a similar level to that of fluoxetine
[198]. With special reference to translational potential, the
effects of combined EPA and fluoxetine treatment were
superior when compared to either intervention alone.
Besides their beneficial roles in unipolar depression, n-3
fatty acids have also been proposed to ameliorate depressive
symptoms in context of bipolar disorder [199]. In addition,
n-3 PUFA supplementation also decreased depressive and
anxiety symptoms in early postmyocardial infarction patients
[200], although some studies failed to show any improvement
in depressive symptoms among this population [201].
Some authors argue that the antidepressant effects of
PUFA are only identifiable within populations with severe,
diagnosed depression [191, 201]. Whilst there is evidence to
support this position in depression, it appears that this is not
the case for anxiety. Indeed, n-3 fatty acid supplementation
reduced symptoms in healthy, nonclinical anxious individu-
als [202].
Together, these findings identify PUFA supplementation
as a potential translational tool in context of mood and anx-
iety disorders; however, depression and anxiety may arise in
different contexts, comorbidwith othermedical conditions—
psychiatric or not—and, thus, the exact doses, onset, and
duration of PUFA supplementation for maximized results
within different patient subsets requires further investigation.
5.4. Impact of PUFA on Aging
5.4.1. Animal Studies. Supplementation of docosapentaenoic
acid DPA, an intermediate molecule in the metabolism of
DHA from EPA, preserves hippocampal function in the aged
brain as evidenced by elevated measures of enhanced LTP
when compared to control-fed counterparts [203]. Similarly,
EPA has also been reported to preserve LTP in aged rats [67].
These findings complement recent data demonstrating
a positive effect of dietary supplementation with PUFA
on spatial memory in aged mice [203, 204]. Further to
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this, age-related decline in spatial memory performance is
reflected by a decrease in c-Fos expression with age [205]. c-
Fos expression reflects a neuronal response to extracellular
signals such as growth factors and is triggered during action
potentials [205]. Notably, provision of n-3 PUFA attenuates
age-related declines in c-Fos expression [204].
Other studies, however, have reported little or no protec-
tive effects of DHA/EPA-enriched diets on aged-associated
cognitive decline [174]. Such discrepancies in the literature
are likely attributable to differences in length and/or compo-
sition of PUFA supplementation.
The positive effects of PUFA supplementation upon age-
related cognitive decline in animals are likely governed by
antioxidant [203] and anti-inflammatory mechanisms [204].
It will be of great interest to further explore howmechanisms
related to brain plasticity also putatively contribute to PUFA-
mediated reversal of age-related cognitive decline.
5.4.2. Human Studies. Evidence from observational studies
largely suggests that n-3 enriched diets may protect individ-
uals from or slow down cognitive decline in the elderly pop-
ulation [206, 207]. For example, van Gelder and colleagues
report results from a 5-year population-based prospective
study of cognitive decline in relation to fish, EPA, and DHA
consumption in a cohort of 210 nondemented elderly men
(age range: 70–89) from the Netherlands [208]. Multivariate
linear regression analyses revealed that, among individuals
consuming fish, cognitive decline was significantly lower
when compared to their counterparts who consumed no
fish [208]. Further to this, the authors reported a dose-
response relation between increased intake of EPA+DPA
and less cognitive decline. Similarly, a 5-week crossover
trail evaluating the impact of fish oil n-3 PUFA intake on
cognitive performance revealed that PUFA supplementation
in a Swedish cohort of 40 healthy middle-aged to elderly
subjects (mean age: 63 ± 5 years) significantly improved
working memory [209].
In a recent study, Titova and coworkers explored whether
EPA and DPA intake impacted not only cognitive perfor-
mance at 75 years, but also brain volume in a healthy cohort of
252 Swedish participants with a baseline age of 70 and a low
dietary intake of these fatty acids at the start of study [210].
Multivariate analyses revealed that self-reported increases in
EPA and DHA intake at 70 years positively associated with
both cognitive performance and global grey matter volume
[210].
It must be noted that not all clinical studies have reported
a positive relationship between n-3 PUFA consumption and
cognitive performance among the elderly population. For
example, in a sample of 1025 elderly men (mean age: 68
years) from the Boston Veterans Affairs Normative Aging
study, general linear models at both the cross-sectional and
longitudinal levels did not reveal any significant association
between fatty fish or n-3 PUFA intake and performance on
a battery of cognitive tests after a 6-year follow-up [211]. In
addition, a Cochrane review by Sydenham and colleagues
reports that the pooling of data from three randomised-
control trials of high-methodological quality also failed to
show any benefit of n-3 PUFA supplementation on cognitive
function in a sample of healthy elderly persons (age > 60
years), where n-3PUFA supplementation occurred for at least
6months (total 푛 = 3536) [206]. It is possible that a protective
effect of n-3 PUFA intake on cognitive decline may only be
apparent with advancing age and marked cognitive decline.
On the whole, these findings do not support the data
from the animal studies above, whereby n-3 PUFA markedly
improves cognitive function in the aging brain. It is suggested
by Sydenham and colleagues that trials of longer duration are
required to better evaluate protective effects of PUFA sup-
plementation on cognitive function in the elderly population
[206].
5.5. Impact of PUFAs on AD
5.5.1. Animal Studies. The most recent animal findings on
the impact of PUFA on brain plasticity in AD models are
described in Table 3.
Supplementing transgenic mouse models of the disease
with a diet enriched mainly in DHA significantly lowered
the synthesis of 훽-amyloid peptides and the formation of
amyloid plaques [214]. With regard to brain plasticity, EPA
supplementation has been shown to prevent the inhibition of
LTP induced by 훽-amyloid [67].
Apolipoprotein 휀4 (apoE휀4) is a major genetic risk factor
for vascular dementia and sporadic AD [215]. Interestingly,
when compared to the apoE휀2 and apoE휀3 isoforms, apoE휀4
functions inefficiently as a cholesterol transporter [216, 217],
potentially impacting synaptogenesis and synaptic mainte-
nance through altered release of cholesterol [218]. Further to
this, maintaining mice with compromised apoE휀4 function
on a fish-oil diet resulted in improved behavioral and cogni-
tive performance [219].
It is posited that that enhanced beneficial effects can
come from multidietary approaches, rather than from the
supplementation of a single nutrient to patients at risk or
diagnosed with AD [220]. In order to explore the mechanism
by which multidietary nutrients putatively protect against
AD, Jansen and colleagues investigated the effects on, among
others, neural plasticity markers and associated behavior in
apoE4-carrier and apoE knockout mice of a diet containing
DHA, EPA, phospholipids, uridine monophosphate (UMP),
choline, B vitamins, and antioxidants [213].
At the behavioral level, the multinutrient diet exerted
anxiolytic effects for both apoE ko and wild-type mice;
an important effect given that anxiety and restlessness
are significantly correlated with impairments in activi-
ties of daily living in AD [221]. Further to this, Jansen
and colleagues also reported that the multinutrient diet
improved learning and spatial memory, but only in the
apoE ko mice. This diet-associated improvement in cog-
nition was independent of any change in synaptophysin-
labelled presynaptic boutons and in the number of neu-
roblasts in the DG. These observations are in line with
previous reports that failed to demonstrate an effect of n-
3 PUFA diets on synaptophysin levels; instead, it appears
that n-3 PUFAs exert their beneficial effects by improving
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synaptic function rather than synaptogenesis [219, 222].
With regard to the negative neuroblast finding, many studies
reporting a positive effect of n-3 PUFA, folic acid, and
vitamins and antioxidants on neurogenesis do so when
making comparisons against nutrient-deficient animals [178,
223].This suggests that the beneficial effects of dietary inter-
ventions might become apparent only when neurogenesis is
severely compromised, as is the case during dietary deficiency
but not in the apoE4 and apoE ko mice.
In a separate but similar study, Jansen and coworkers
further affirm the anxiolytic effect of the PUFA-diet enriched
with phospholipids, choline, folic acid, vitamins B6, B12, C,
E, and selenium in a transgenic mouse model of AD [175].
Notably, n-3 PUFA on its own did not exert these effects,
suggesting that it is the combination of additional nutrients
which underlies the reductions in anxiety-like behaviour in
this mousemodel of AD. Both the PUFA only and PUFA plus
additional nutrients diet had no effect in attenuating spatial
learning, but mice in the latter group did show significant
increases in doublecortin positive cells, suggesting that the
multinutrient diet restored neurogenesis in this model of AD
[175].
5.5.2. Human Studies. Epidemiological studies suggest a role
of n-3 PUFAs in slowing cognitive decline among elderly
individuals and thus in reducing the incidence of AD [224].
For example, Morris and colleagues conducted a prospective
population-based study of 815 initially healthy individuals
(age range: 65–94) from the Chicago Health and Aging
Project, reporting that after an average of 3.9 years follow-up
the increased intake of DHA but not EPAwas associated with
a reduced risk of AD [225]. More recently, a study compared
the plasma levels of EPA and DHA among individuals
(age range: 55–91 years) with cognitive impairment but no
dementia (푛 = 55), patients with AD (푛 = 19), and
healthy volunteers (푛 = 61). Across the whole sample,
dietary intake of n-3 fatty acids, plasma DHA, and plasma
EPA positively predicted performance of delayed and verbal
recognition memory [226]. Further research is needed to
determine whether reduced levels of PUFA are secondary to
AD or contributors to disease pathophysiology and cognitive
decline. Interestingly, supplementation with n-3 PUFA has
also been shown to exert beneficial effects on depressive
symptoms and agitation in patients with mild to moderate
AD [227], complementing many of the findings described in
the animal studies section (Tables 2 and 3).
Intervention studies based on supplementation with n-3
PUFA, however, have proved to be disappointing, with many
studies failing to show any protective effect against AD or
cognitive decline except in some AD patients with very mild
cognitive impairment [228]. The failure of these interven-
tions, at least in part, are attributable to the testing in patients
already withmild tomoderate dementia, a too late time point
in the pathophysiological course of AD [229]. In addition,
these negative results may reflect intrinsic limitations in
the design of these trials such as the preponderance to
recruit healthier elderly participants who are moremotivated
to adhere to instructions to eat healthier and undertake
exercise more, thus confounding results by not being a truly
representative sample of the target population [167].
As described above, many other dietary compo-
nents/regimens possess diverse properties to promote
brain plasticity. Considering the complementary roles of
polyphenols and PUFA, it is not surprising that the specific
multinutrient diets containing a combination of these factors
have been developed to mitigate risk factors associated
with AD [230]. Indeed, two randomized, double-blind
controlled clinical trials reported that daily consumption
of such multinutrient component diets improved memory
performance in patients with mild AD [230, 231].
In summary, whether the lack of agreement between
mechanistic studies in animals and observational data in the
trial setting represents poor efficacy of n-3 PUFA in mitigat-
ing AD-induced cognitive decline or intrinsic limitations of
trial design remains an open question [228].
6. Discussion
6.1. Animal and Human Studies: Bridging the Gap. The
marked contribution of poor dietary habits to the ever
growing prevalence of neurological and psychiatric dis-
eases is increasingly recognized [232]. Many of the animal
studies and indeed some of the human studies described
above demonstrate that diet-induced brain plasticity offers
tremendous potential in promoting emotional and cognitive
well-being across a variety of contexts. In particular, diet
influences multiple aspects of brain plasticity, including neu-
rodevelopment, neurotrophins, neurogenesis, synaptogene-
sis, and ultimate activity at the brain network level (Figure 1).
Together these processes underlie and influence cognitive
and mood/emotional processing, thus positioning diet as a
key modulator of brain structure and function.
Importantly, diet-induced brain plasticity is putatively a
low-cost and effective means to protect against the debili-
tating effects of psychiatric and neurological disorders. This
viewpoint is strongly supported by many of the cellular and
molecular animal studies discussed which together indicate
that in addition to being a noninvasive intervention diet
entails a “broad spectrum of action” [233]. Notably, the wide
range of cellular and molecular mechanisms engaged by
dietary factors and regimens such as CR, IF, polyphenols, and
PUFAs can be advantageous for the treatment of neurological
disorders characterized by diffuse pathology and deficits
across multiple cellular domains. This indicates that diet
has strong translational potential and is further supported
by the promising results from epidemiological studies that
have shown that these dietary factors entail improvements in
emotional and cognitive domains in humans [153, 209, 234].
We now discuss some of the other factors involved in
the so-called translational gap, namely, important caveats
and obstacles that must be considered if diet-induced brain
plasticity is to be successfully implemented in the clinical
setting.
6.2. Combining Diet and Exercise. Feeding and exercising
are complementary aspects of regulating energy balance that
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Figure 1: Different dietary interventions in animal and human studies are believed to modulate various aspects of brain plasticity and in
turn influence behaviour. Animal studies provide the vast majority of our current mechanistic understanding of the potential mechanisms by
which dietary interventions impact brain plasticity. Further mechanistic studies aiming to fill the gap in our understanding of how diet can
modulate plasticity and promote mental health in human populations are clearly needed. Moreover, additional intervention studies are also
required to demonstrate efficacy, enabling the safe translation of such dietary interventions into clinical practice or incorporated into our daily
lifestyles to enhance brain health/function and well-being. In red, effects induced by CR; in purple, effects induced by IF; in green, effects
induced by supplementation with polyphenols; in orange, effects induced by PUFAs. AD: Alzheimer’s disease; AHN: adult hippocampal
neurogenesis; BDNF: brain-derived neurotrophic factor; CBF: cerebral blood flow; CBV: cerebral blood volume; CORT: corticosterone;
CR: calorie restriction; CREB: cAMP responsive-element binding; 5-HT: 5-hydroxytryptamine; IF: intermittent fasting; GR: glucocorticoid
receptor; LTP: long-termpotentiation;MAO-A:monoamine oxidaseA;NMDAR:N-methyl-D-aspartate receptor; NE: noradrenaline; NPY-1:
neuropeptide Y type 1 receptor; PUFAs: polyunsaturated fatty acids.
have influenced the evolution of the modern brain over
thousands of years [124]. Given that the brain poses the
largest demand on oxygen consumption, it is not surprising
that energy metabolism has a profound influence on brain
function [127]. In particular, both food consumption and
physical activity stimulate mitochondrial activity and thus
energy provision to the brain which in turn modulates the
signaling pathways linked to neuronal function and brain
plasticity [127].
In addition to its role in enhancing brain plasticity,
BDNF has also been implicated in modulating brain energy
metabolism, as evidenced by studies that demonstrate that
perturbed BDNF signaling can manifest in metabolic disor-
ders such as obesity [45]. Together, these studies reveal that
BDNF plays a key role in both brain energy metabolism and
plasticity, demonstrating a strong and influential relationship
between diet, exercise, and brain function [45, 127].
Similar to diet, exercise entails a “broad spectrum of
action” and also effectively promotes brain plasticity through
the increases of neurogenesis, neurotrophins levels, and
synaptic plasticity [235]. Indeed, it is possible that exercise
potentiates the health-promoting effects of diet components
and vice versa at the cellular and molecular levels. For
example, it has recently been demonstrated that exercise
works in tandem with a DHA-enriched diet to enhance
cognitive function [236]. In particular, exercise appears to act
onmechanisms that preserve DHA on the plasmamembrane
and in turn enhance neurotransmission [233]. In addition,
the concurrent effects of DHA diet and exercise engage
BDNF-mediated synaptic plasticity [237].
Further to this, in a rodent model of traumatic brain
injury (TBI), the combination of DHA supplementation
and voluntary exercise restored membrane homeostasis to
counteract the detrimental effects of TBI onmany parameters
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of synaptic plasticity and cognition [238]. With regard to
synaptic plasticity, exercise greatly enhanced the action of
DHAsupplementation on levels of BDNFandTrkB activation
following TBI [238]. Together, these data reveal a strong
and novel interaction between diet and exercise, whereby
aspects of these lifestyles intersect at the molecular level
under pathological conditions to promote brain plasticity
[238].
Similarly, exercise and flavonoid-enriched diets together
promote the elevation of genes that promote brain plasticity
whilst decreasing expression of markers known to compro-
mise this plasticity, including those related to inflammation
and cell death [239]. Moreover, exercise has also been shown
to markedly reduce the effects of a diet rich in saturated
fats through the counteracting of declines in BDNF-mediated
synaptic plasticity in the hippocampus [240].
The combination of exercise and CR is particularly
noteworthy. In this paradigm, typically, 12.5% of the energy
restriction comes from adherence to a restricted diet and
the other 12.5% comes from increased energy expenditure
via exercise [33]. The principal advantage of combining CR
with exercise is that individuals may find it easier to comply
with energy restriction if this split between CR and exercise-
induced expenditure [241]. Therefore CR plus exercise may
well prove viable and effective means of promoting brain
plasticity. Some studies, however, have reported that CR plus
exercise does not elicit positive changes to health other than
those elicited by CR. For example, animals maintained on an
80% CR plus exercise regimen demonstrated no significant
changes in oxidative stress, in proinflammatorymarkers [242,
243], or upon extension of life span [244].
6.3. Diet-Induced Brain Plasticity in the Modern World. In a
thought-provoking study, Agrawal andGomez-Pinilla reason
that “unhealthy dietary habits are difficult or almost impossi-
ble to completely eliminate” and that this grim reality neces-
sitates the concurrent supplementation of healthier dietary
components to popular diets as a strategy to counteract
metabolic dysfunction in the brain and ultimately to protect
mental health [245]. In particular, these authors investigated
whether a DHA-enriched diet could counteract the debilitat-
ing effects of insulin resistance on brain plasticity. Deficiency
of n-3 exacerbated a decline in spatial memory performance
in proportion to the intensity of insulin resistance. Further to
this, the authors observed that rats fed with the n-3 diet were
able tomaintain the ratio of n-6/n-3within the normal range,
even in the presence of fructose, indicating preservation
of membrane fluidity and in turn promotion of synaptic
plasticity and cognition [245].
Further to this, n-3 deficiency decreases phosphorylation
of CREB and reduces the levels of two markers of synaptic
plasticity—synapsin I and synaptophysin [245]. Importantly,
fructose consumption potentiated this effect. Together, data
from this study implies that adequate levels of DHA are
particularly necessary under challenging conditions such as
the metabolic syndrome, and given the abundant consump-
tion of sugars in western society, proper consumption of
DHA emerges may be an important means to preserve brain
plasticity.
6.4. The Challenge of Imaging Brain Plasticity. Whilst cogni-
tive behavioral testing in human subjects and animals is a
necessary and appropriate means of assessing brain plasticity
following dietary intervention, there is a pressing need to
relate cognition, mood/emotionality, and behavior to in vivo
structural and dynamic quantitative assessments which will
enable direct inference of a diet-induced effect on the brain
[125]. We have described above several examples whereby
AHN appears to be enhanced following dietary intervention
but investigation of both the dynamics and functions of AHN
in humans has remained challenging owing to the absence of
accepted macroscopic neuroimaging readouts [246].
Brain imaging studies utilizing fMRI and transcranial
Doppler ultrasound have revealed that efficient cerebral
blood flow (CBF) is integral to optimal brain function as
evidenced by marked reductions in CBF among individuals
with impoverished cognitive performance and patients diag-
nosed with dementia [247, 248]. As such, the observation
that 1-2 hour infusion of subtypes of polyphenol markedly
and rapidly increases CBF measures in human subjects is of
great interest [249, 250]. Further to this, intervention with
a flavonol-rich drink derived largely from cocoa increased
blood flow, asmeasured by the blood oxygen level-dependent
(BOLD) signal on fMRI, in certain regions of the brain as well
as modifying the BOLD response during a task switching test
[249]. Whilst these studies primarily focus on the flavanol
subset of polyphenols (e.g., cocoa), it is highly plausible to
suggest that other polyphenols, particularly those rich in
other flavonols such as grapes and blackcurrants, may also
impact positively CBF [125].
More definitive proof of diet-induced brain plasticity will
require such fMRI measures to be compared with changes
in regional grey matter volume as well as biomarkers of
NSCs using proton NMR spectroscopy [125]. As such, by
combining a multimodal neuroimaging, biochemical, and
behavioral approach, the effects of diet on brain plasticity
will be better illuminated in a mechanistic, dynamic, and
quantitative way. Despite these challenges, the diet field can
take inspiration from a recent study by Voss and colleagues
that assessed the effects of exercise on brain plasticity in
combination with fMRI investigation [87].
6.5. Animal versus Human Brain Plasticity. Perhaps more
important than the technical challenges described in
Section 6.4, with regard to trying sensitively capturing
dynamic processes such as neurogenesis in the human brain,
is to acknowledge possible fundamental neurobiological
and functional differences related to brain plasticity when
extrapolating from findings in animals to humans. Taking
adult hippocampal neurogenesis as an example, whilst
the levels of this process appear comparable in middle-
aged rodents and humans [251], it is now appreciated
that age-related declines in rodents are potentially more
pronounced than in humans [251, 252]. Such an observation
has implications for dietary regimens known to specifically
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increase neurogenesis in older animals, as there is a
possibility that these same regimens will not elicit the
same magnitude of increases because the baseline levels of
neurogenesis are potentially higher in elderly humans.
These remarks, however, do further emphasize the need
for improved in vivo temporal and spatial resolutions ofNSCs
in both animals andhumans, in order to facilitate robust com-
parisons as well as quantitatively determine changes in the
levels of NSCs during and following a dietary intervention.
6.6. Genetic Interaction. Diet-gene interactions are pivotal in
mediating the effects of diet-induced brain plasticity, with
subsequent effects on brain (patho)physiology [253]. Indeed,
single nucleotide polymorphisms, copy number variants,
modifications to the epigenome as well as the activity of
microRNAs, and long noncoding RNAs can all modify the
effects of nutrition on gene expression [253].
Intriguingly, a recent study reported that 9 dietary
polyphenols appear to counteract the modulation of dif-
ferentially expressed miRNAs in apoE knockout mice, sug-
gesting that polyphenols engage similar mechanisms [254].
Whilst the precise functions of these miRNAs remain to
be elucidated as well as the extent of the influence of the
ApoE genotype on modulating the effects of polyphenols on
miRNA expression, this type of study clearly demonstrates
that diet-gene interaction is yet another important player and
requires further investigation [253].
More generally, animal studies afford the possibility to
investigate the impact of interventions on a genetically
homologous cohort. In contrast, extrapolating findings from
such animal studies to heterogeneous humans necessitates
caution owing to varying genetic backgrounds of partici-
pating subjects. Moreover, this heterogeneity also limits the
generalizability from one population to another owing to
differences in factors related to lifestyle and ethnicity.
6.7. Supplementation and BBB Permeability. DHA has a
multitude of actions at the cellular and molecular level,
making it difficult to ascribe recommended levels of intake
[124]. Indeed, a number of studies have demonstrated that
a varied range of n-3 intake can have beneficial effects on
mental health [255]. It must be emphasized that these effects
are dependent on the length of supplementation and are likely
to be influenced by baseline levels [124].
Current recommendations issued by the dietary sup-
plement industry for resveratrol are 20mg per day but it
must be stressed that these recommendations are not specific
to enhancing synaptic plasticity or exerting an effect on
brain function [255]. As such, clinical applications of dietary
polyphenols supplementation in context of emotional health
or neurodegenerative disease demands further research [124].
Owing to the effects of gut enzymes on the metabolism
of polyphenols, their metabolites exhibit a wide range
of bioavailability [256]. The ability of the metabolites of
polyphenols to cross the blood brain barrier (BBB) is a
major determinant of their bioavailability to brain cells [127].
Importantly, many polyphenols have been claimed to exert
neuroprotective effects but many polyphenols have also been
demonstrated to be incapable of crossing the BBB, suggesting
that their suggested benefits to the brainmay arise via indirect
or other pathways [127]. As reviewed above, the identification
and profiling of bioavailability and pharmacokinetics of
specific metabolites of polyphenols by Wang et al. 2012 [159]
and Ho et al. 2013 [160] that not only penetrate the BBB but
also act on AD neuropathology as well as promote neuronal
plasticity provide two considered examples of attempts to
translate the observed epidemiological benefits of grape-
derived products and red wine in AD into clinical applica-
tions.
6.8. Ethical and Socioeconomic Considerations. It must be
noted that the long-term effects of CR (over 1 year) in
elderly persons remain to be elucidated and as such caution
must be followed before engaging in a CR regimen [97].
Whilst there are encouraging signs from studies in animal
models regarding the benefit of CR and/or IF to mitigate or
delay the onset of AD, it must be noted that malnutrition
is a common problem among the elderly; as such, dietary
recommendations will have to take into consideration this
background [98].
In addition, it is not known whether the putative benefits
of CR are confined to the restriction period or long lasting
after the intervention, of which the length also remains to be
determined [97]. More likely, CR will be the most effective
when undertaken in conjunction with exercise or intellectual
and environmental enrichment [97]. Given these concerns,
IF appears a more feasible option for humans rather than
lifelong CR which may prove to be difficult to adapt to over a
lifetime [112]. Further to this, reports have shown that long-
term CRmay entail detrimental effects on cognitive ability in
middle- and old-aged rats, attributable to low blood glucose
levels [257].
Socioeconomic position (SEP) as determined by param-
eters such as income, education, and occupation is an
important determinant of dietary intake with higher SEP
generally related to better diet quality [258]. Interestingly,
SEP is also associated with differences in cognitive function
across life [259, 260]. Like diet, animal evidence suggests
that conditions simulating SEP modulate neurobiological
mechanisms implicated in brain plasticity and the structural
and functional changes in response to these life experiences
[261].
Parrott and colleagues investigated whether SEP influ-
ences the impact of diet quality on cognitive function. They
observed that cognitive benefits of adherence to a “prudent”
(healthy) dietary pattern were garnered regardless of SEP.
These benefits were also differential; for example, higher
adherence to this diet was associated with less decline in
those with low SEP, whereas it was associated with better
performance among those with high SEP [262].The authors
propose that these findings are consistent with the concept of
cognitive reserve, whereby individual differences in lifestyle
may allow for more successful accommodation of age-related
brain changes by protecting the amount of neural substrate
or the efficiency of brain networks mediating performance
[263].
24 Neural Plasticity
7. Conclusion
Whilstmuch remains to be elucidated at themechanistic level
in both animal and humans, the current literature provides
robust evidence for the essential roles played by dietary fac-
tors in promoting brain plasticity. Animal studies reveal that
a multitude of dietary regimens and components increase the
levels of adult hippocampal neurogenesis and neurotrophins
as well as acting to enhance synaptic function.These cellular
andmolecular changes likely underlie marked improvements
in cognitive performance and emotional regulation across a
number of disease contexts in animals maintained or supple-
mented on these different dietary regimens. Moreover, this
inference is supported by the largely positive epidemiological
studies, positioning diet as an important factor in disease risk,
progression, and severity.
Taken together, we argue that whilst the field must be
mindful of the “gap” between the effects of diet across animal
and human studies it is by no means insurmountable and
perhaps smaller than first envisaged. Importantly, future
dietary intervention studies must take into account timing of
treatment onset and its duration; synergistic/additive effects
with multiple dietary components and exercise; longitudinal
andmultimodalmeasurements; the longevity of diet-induced
effects. It can be concluded that an appropriate dietary
intake, encompassing the aforementioned considerations—
food amount, frequency, and content—should be actively
encouraged as a cost-effective, noninvasive, and broad spec-
trum public health initiative for both the prevention and
amelioration of neuropsychiatric disorders.
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